Xanthohumol

Pharmacology & Research

Xanthohumol is the principal prenylated chalcone of hops (Humulus lupulus), and therefore occurs in small amounts in beer. Its story turns on two facts. First, its chemistry is transformative: xanthohumol isomerises to the flavanone isoxanthohumol (notably during brewing, so beer is richer in isoxanthohumol) and is then converted by gut bacteria to 8-prenylnaringenin — the most potent known phytoestrogen — which is where its hormonal caution comes from, not the parent itself. Second, its pharmacology is real but preclinical: strong metabolic, anticancer and anti-inflammatory activity across cells and rodents ^{1,4Reference 1Girisa S et al. · 2021Xanthohumol from hop: hope for cancer prevention and treatmentView study →Reference 4Neumann HF et al. · 2022Bioavailability and cardiometabolic effects of xanthohumol: evidence from animal and human studiesView study →}, with completed human safety and pharmacokinetic trials but no efficacy trial ^{9,10Reference 9Langley B et al. · 2021Xanthohumol microbiome and signature in healthy adults (the XMaS trial): safety and tolerability results of a Phase I trialView study →Reference 102026RCTThe bioavailability of xanthohumol in humans and the influence of formulation and dose: a randomised controlled trialView study →}, all limited by poor oral bioavailability ^{2Reference 2Harish V et al. · 2021Xanthohumol for human malignancies: chemistry, pharmacokinetics and molecular targetsView study →}.

1. Metabolic / cardiometabolic

The strongest area. In high-fat-diet and diabetic mice, xanthohumol improved lipid and glucose metabolism in liver and muscle and reduced weight and adiposity ^{3Reference 3Costa R et al. · 2017AnimalXanthohumol and 8-prenylnaringenin ameliorate diabetic-related metabolic dysfunctions in miceView study →}, as synthesised in cardiometabolic reviews ^{4,5Reference 4Neumann HF et al. · 2022Bioavailability and cardiometabolic effects of xanthohumol: evidence from animal and human studiesView study →Reference 5Gómez-Zorita S et al. · 2024Beneficial effects of xanthohumol on metabolic syndrome: evidence from in-vitro and animal-model studiesView study →}. But the completed human work is deliberately scoped: a Phase I trial found 24 mg/day safe over 8 weeks ^{9Reference 9Langley B et al. · 2021Xanthohumol microbiome and signature in healthy adults (the XMaS trial): safety and tolerability results of a Phase I trialView study →}, and a formulation RCT showed micellisation boosts absorption yet 172 mg of micellar xanthohumol had no acute effect on resting energy expenditure, blood pressure or heart rate ^{10Reference 102026RCTThe bioavailability of xanthohumol in humans and the influence of formulation and dose: a randomised controlled trialView study →}.

Gap: no human efficacy endpoint has been demonstrated — a grant-funded metabolic-syndrome RCT has no indexed clinical-outcome publication — the animal doses are unattainable from hops or beer, and oral bioavailability is poor ^{10,4Reference 102026RCTThe bioavailability of xanthohumol in humans and the influence of formulation and dose: a randomised controlled trialView study →Reference 4Neumann HF et al. · 2022Bioavailability and cardiometabolic effects of xanthohumol: evidence from animal and human studiesView study →}.

2. Anticancer

Xanthohumol is antiproliferative, pro-apoptotic, anti-angiogenic and anti-metastatic across many tumour lines, with well-catalogued mechanisms (NF-κB, apoptosis, angiogenesis) ^{1,2Reference 1Girisa S et al. · 2021Xanthohumol from hop: hope for cancer prevention and treatmentView study →Reference 2Harish V et al. · 2021Xanthohumol for human malignancies: chemistry, pharmacokinetics and molecular targetsView study →}.

Gap: zero human efficacy data; registered human trials address pharmacokinetics and DNA-damage biomarkers, not cancer outcomes, and effective concentrations far exceed dietary exposure ^{2Reference 2Harish V et al. · 2021Xanthohumol for human malignancies: chemistry, pharmacokinetics and molecular targetsView study →}.

3. Anti-inflammatory / antioxidant

Consistent NF-κB suppression and Nrf2-driven antioxidant induction across cell and rodent models — the mechanistic thread under most of xanthohumol’s other effects ^{1,12Reference 1Girisa S et al. · 2021Xanthohumol from hop: hope for cancer prevention and treatmentView study →Reference 122023Xanthohumol protects against acetaminophen-induced hepatotoxicity via Nrf2 activation through the AMPK/Akt/GSK3β pathwayView study →}.

Gap: entirely preclinical, with no completed human inflammation trial ^{1Reference 1Girisa S et al. · 2021Xanthohumol from hop: hope for cancer prevention and treatmentView study →}.

4. Hepatoprotective

Xanthohumol protected against acetaminophen-induced hepatotoxicity via Nrf2 activation through the AMPK/Akt/GSK3β pathway in mice ^{12Reference 122023Xanthohumol protects against acetaminophen-induced hepatotoxicity via Nrf2 activation through the AMPK/Akt/GSK3β pathwayView study →} and reduced hepatic steatosis in high-fat-diet rats via AMPK activation with lower SREBP1c and ACC-1 ^{11Reference 112023AnimalThe hepatic antisteatosis effect of xanthohumol in high-fat-diet-fed rats entails activation of AMPKView study →}.

Gap: rodent-only, with no human liver-endpoint data, overlapping mechanistically with the metabolic story ^{11,12Reference 112023AnimalThe hepatic antisteatosis effect of xanthohumol in high-fat-diet-fed rats entails activation of AMPKView study →Reference 122023Xanthohumol protects against acetaminophen-induced hepatotoxicity via Nrf2 activation through the AMPK/Akt/GSK3β pathwayView study →}.

5. Antimicrobial

Purified xanthohumol strongly inhibits gut anaerobes including Clostridium difficile and shows positive co-action with some antibiotics ^{6Reference 6Čermák P et al. · 2017Strong antimicrobial activity of xanthohumol and other hop derivatives on gut anaerobic bacteriaView study →}.

Gap: in-vitro exclusively, with no in-vivo or clinical infection data, and poor oral exposure makes systemic relevance doubtful ^{6Reference 6Čermák P et al. · 2017Strong antimicrobial activity of xanthohumol and other hop derivatives on gut anaerobic bacteriaView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
NF-κB (↓)	↓ pro-inflammatory transcription; pro-apoptotic in tumour cells	anti-inflammatory, anticancer
Nrf2 (↑, via AMPK/Akt/GSK3β)	induces antioxidant/phase-II enzymes	antioxidant, hepatoprotective
AMPK (↑)	↓ de-novo lipogenesis (SREBP1c, ACC-1 ↓)	metabolic, hepatic antisteatosis
PPAR modulation; DGAT inhibition	altered lipid/glucose gene expression; ↓ triglyceride synthesis	metabolic / anti-obesity
Pro-apoptotic / anti-angiogenic (caspase, VEGF)	tumour-cell death, reduced neovascularisation	anticancer

Pharmacokinetics

Load-bearing and the central limitation of the whole molecule. Xanthohumol has poor oral bioavailability from low aqueous solubility and extensive first-pass metabolism (glucuronidation/conjugation) ^{2,4Reference 2Harish V et al. · 2021Xanthohumol for human malignancies: chemistry, pharmacokinetics and molecular targetsView study →Reference 4Neumann HF et al. · 2022Bioavailability and cardiometabolic effects of xanthohumol: evidence from animal and human studiesView study →}. It isomerises to isoxanthohumol — notably during brewing, so beer carries more isoxanthohumol than xanthohumol ^{7Reference 7Stevens JF · 2004Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/15231405/View study →} — and isoxanthohumol is then O-demethylated by gut bacteria to 8-prenylnaringenin (8-PN), the potent phytoestrogen; this is the main dietary route to 8-PN, and interindividual gut-flora variation makes 8-PN yield highly variable ^{7Reference 7Stevens JF · 2004Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/15231405/View study →}. Formulation matters: micellisation substantially raises Cmax and AUC in humans across an 86–172 mg range ^{10Reference 102026RCTThe bioavailability of xanthohumol in humans and the influence of formulation and dose: a randomised controlled trialView study →}. Reassuringly, a human hop-supplement probe study found no clinically significant effect on CYP2C9, 1A2, 2D6 or 3A4 ^{8Reference 8van Breemen RB et al. · 2020Pharmacokinetic interactions of a hop dietary supplement with drug metabolism in perimenopausal and postmenopausal womenView study →}.

Clinical trials

There is no completed human efficacy trial for any indication. The human data are pharmacokinetics, safety and one bioactivity readout: the XMaS Phase I trial found 24 mg/day of pure xanthohumol over 8 weeks safe and well-tolerated ^{9Reference 9Langley B et al. · 2021Xanthohumol microbiome and signature in healthy adults (the XMaS trial): safety and tolerability results of a Phase I trialView study →}; a bioavailability RCT confirmed micellisation improves absorption but found no acute effect of 172 mg on metabolic endpoints ^{10Reference 102026RCTThe bioavailability of xanthohumol in humans and the influence of formulation and dose: a randomised controlled trialView study →}; and a grant-funded metabolic-syndrome RCT (20/60 mg) has no indexed clinical-outcome publication and should be treated as unpublished, not as positive evidence. A Phase II XMaS trial in Crohn’s disease is protocol-registered.

Last checked: July 2026.

Toxicity & Safety

Xanthohumol has generally low toxicity — it has been consumed in small amounts via beer for centuries, and 24 mg/day for 8 weeks was safe in the Phase I trial with no serious adverse events and wide preclinical safety margins ^{9Reference 9Langley B et al. · 2021Xanthohumol microbiome and signature in healthy adults (the XMaS trial): safety and tolerability results of a Phase I trialView study →}. The important nuance is that the estrogenicity concern is a metabolite story, not xanthohumol’s own: the parent chalcone is essentially non-estrogenic, and the hormonal risk is the gut-derived 8-prenylnaringenin via the isoxanthohumol pathway ^{7Reference 7Stevens JF · 2004Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/15231405/View study →} — a caution inherited by concentrated supplemental doses, and the reason supplement safety is “not fully characterised.” On interactions, a human study found no clinically significant CYP2C9/1A2/2D6/3A4 effect from a hop supplement ^{8Reference 8van Breemen RB et al. · 2020Pharmacokinetic interactions of a hop dietary supplement with drug metabolism in perimenopausal and postmenopausal womenView study →}, though theoretical caution with hormone-sensitive therapy is warranted given the 8-PN route.

Pregnancy & lactation

Avoid. Because gut metabolism yields 8-prenylnaringenin, a highly potent phytoestrogen, concentrated xanthohumol or hops supplements should be avoided in pregnancy and lactation, and there is no human reproductive-safety data for supplemental xanthohumol.

Dosage

There is no established therapeutic dose, and nothing here is a recommendation. The human safety trial used 24 mg/day of pure xanthohumol over 8 weeks ^{9Reference 9Langley B et al. · 2021Xanthohumol microbiome and signature in healthy adults (the XMaS trial): safety and tolerability results of a Phase I trialView study →}; pharmacokinetic studies used single doses of 86–172 mg (micellar formulation markedly improving absorption over native powder) ^{10Reference 102026RCTThe bioavailability of xanthohumol in humans and the influence of formulation and dose: a randomised controlled trialView study →}; and the grant-stage metabolic-syndrome trial used 20 mg and 60 mg once daily with unpublished outcomes. Dietary intake from beer is on the order of micrograms to low milligrams and delivers isoxanthohumol and 8-prenylnaringenin more than xanthohumol itself.

References